CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Shares in Smiths Group rise on upbeat full-year results

By Rob Griffin

08:57, 28 September 2021

Smiths logo under magnifying glass
Smiths Group logo on the website homepage – Photo: Shutterstock

Shares in Smiths Group jumped today after the UK industrial technology company revealed group revenue growth was expected to return to pre-Covid levels this year.

The company said it was well-positioned with good order book momentum – despite economic uncertainty and supply chain challenges.

Smiths also announced it had entered into a binding share purchase agreement in relation to the sale of Smiths Medical to ICU Medical for $2.4bn (£1.76bn).

The Board proposes to return 55% of the initial net cash proceeds of the sale – equivalent to £737m – to investors via a share buyback.

Final dividend

The FTSE 100 conglomerate reported underlying revenue down 2% to £2.4bn for the year ending 31 July 2021, with operating profit increasing 7% to £372m.

It also proposed a final dividend of 26p for the full year, representing an increase of 8% over last year’s 35p per share payout.


0.52 Price
-0.710% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00334


27,223.85 Price
+0.020% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00


14,557.80 Price
+0.640% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 3.0


1,948.36 Price
-1.480% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0103%
Overnight fee time 21:00 (UTC)
Spread 0.30

Today’s news was enough to lift the company’s share price up 3% to £14.05 in early trading on the London markets.

Robust performance

Paul Keel, group CEO, said it was an exciting time for the company, which had “high quality businesses with strong fundamentals”.

He also insisted it was well-positioned in markets with near-term upside and attractive long-term growth drivers.

“We are building good momentum and are positioned for growth in our core industrial technology business,” he said. “Smiths is pointed in the right direction and our focus now is squarely on acceleration – acceleration of delivery, acceleration of growth, and acceleration of value creation.”


Read more: Smiths Group sells medical division in .3bn deal

Rate this article

Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 535.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading